Physician profile
Patrick Farrell
NPI 1053765487
$1,081.08
in general payments reported to CMS, 2019-2025
16 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $230 · 2024: $675 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $205.00 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $195.46 | 2023-2024 | Farxiga, Airsupra |
| Pfizer INC. | $176.01 | 2023-2025 | |
| Abbvie INC. | $88.32 | 2023-2024 | |
| Astellas Pharma US INC | $86.51 | 2023-2025 | Veozah |
| Lilly USA, LLC | $76.10 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $43.26 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $41.30 | 2024-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $37.86 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Otsuka America Pharmaceutical, INC. | $33.21 | 2023-2024 | Rexulti |
| Sanofi Pasteur INC. | $22.66 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.33 | 2024 | Caplyta |
| Currax Pharmaceuticals LLC | $15.61 | 2023 | Contrave, Onzetra Xsail |
| Idorsia Pharmaceuticals US INC | $15.39 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $13.86 | 2024 | Arexvy, Trelegy Ellipta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.20 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Farrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.